Peptide News
A static news aggregator refreshed from FDA MedWatch, PubMed, and ClinicalTrials.gov so the site can surface real signal without inventing headlines.
Latest sync: May 14, 2026, 11:32 PM. This page favors official and public primary sources over generic news scraping.
Display order is chronological from newest to oldest; future-dated or recently indexed items are pushed to the end.
Status: live
Status: live
Status: live
Compounding Quality Center of Excellence | Instructor-Led Trainings
The Compounding Quality Center of Excellence’s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.
What moved most recently
Newly surfaced trials, FDA action, and PubMed additions sorted with the newest items first.
Newest peptide and GLP-1 updates
A rolling stream of the most recent official and public-source items in the tracker. Future-dated PubMed indexing artifacts stay at the bottom.
Compounding Quality Center of Excellence | Instructor-Led Trainings
The Compounding Quality Center of Excellence’s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.
Compounding Quality Center of Excellence | Self-Guided Online Trainings
FDA Compounding Quality Center of Excellence’s is providing anytime, anywhere training resources to support outsourcing facilities and other stakeholders in their efforts to enhance the quality of compounded drugs. FDA offers self-guided online courses offering continuing education, webinar recordin
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
Compounders may only compound a drug that includes a bulk drug substance that complies with applicable USP or monograph, are components of an FDA approved drug, or appear on the FDA’s 503A bulks list.
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Retatrutide • RECRUITING • Eli Lilly and Company
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Retatrutide • RECRUITING • Eli Lilly and Company
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
Tirzepatide • NOT_YET_RECRUITING • National Cancer Institute (NCI)
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Tirzepatide • RECRUITING • University of Cincinnati
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
Tirzepatide • NOT_YET_RECRUITING • Las Rías Medical Center
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
Semaglutide • RECRUITING • Psychiatric Centre Rigshospitalet
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
Semaglutide • NOT_YET_RECRUITING • Ludwig-Maximilians - University of Munich
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
Semaglutide • ENROLLING_BY_INVITATION • Novo Nordisk A/S
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
Cardiol Rev • Retatrutide • Journal Article
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
J Clin Med • BPC-157 • Journal Article
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
Int J Mol Sci • BPC-157 • Journal Article
Early Alert: Automated Compounding System Issue from Omnicell
Certain labels used with i.V.Station automated compounding systems may not be detected, leading to mislabeled sterile filled syringes
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
J Med Econ • Tirzepatide • Journal Article
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
J Med Econ • Tirzepatide • Journal Article
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Retatrutide • ACTIVE_NOT_RECRUITING • Eli Lilly and Company
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Ann Med • Semaglutide • Journal Article
Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.
J Affect Disord • Tirzepatide • Journal Article
GIPR:GCGR co-agonism restores normal weight in obese rodents.
Mol Metab • Retatrutide • Journal Article
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports Med • BPC-157 • Journal Article
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Metabol Open • Retatrutide • Journal Article
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Tesamorelin • RECRUITING • Hudson Biotech
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scand J Prim Health Care • Semaglutide • Journal Article
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
Tesamorelin • COMPLETED • University of California, San Diego
Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.
J Med Econ • Tirzepatide • Journal Article
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Tesamorelin • COMPLETED • Massachusetts General Hospital
FDA.gov
Regulatory and enforcement signal from FDA feeds that touch peptides, GLP-1s, compounding, and obesity.
ClinicalTrials.gov
Recently updated or newly visible clinical studies tied to tracked compounds and obesity-adjacent programs.
PubMed
Recent research hits for tracked peptide and GLP-1 terms, with reviews and meta-analyses surfaced when available.
This page is built from a generated JSON snapshot refreshed by scheduled syncs, not from a live browser request. FDA items come from RSS feeds, PubMed items come from NCBI utilities, and study updates come from the ClinicalTrials.gov API. The page is date-ordered for readability, while the underlying generator still scores relevance for homepage surfacing and future editorial modules.